Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial.

Autor: Wang ES; Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. Electronic address: eunice.wang@roswellpark.org., Issa GC; MD Anderson Cancer Center, Houston, TX, USA., Erba HP; Duke Cancer Institute, Durham, NC, USA., Altman JK; Northwestern University-Robert H Lurie Comprehensive Cancer Center, Chicago, IL, USA., Montesinos P; Hospital Universitari i Politècnic La Fe, Valencia, Spain., DeBotton S; Institut Gustave Roussy Service d'Hématologie Clinique, Paris, France., Walter RB; Fred Hutchinson Cancer Center, Seattle, WA, USA., Pettit K; University of Michigan, Ann Arbor, MI, USA., Savona MR; Vanderbilt-Ingram Cancer Center, Nashville, TN, USA., Shah MV; Mayo Clinic, Rochester, MN, USA., Kremyanskaya M; Icahn School of Medicine at Mount Sinai, New York, NY, USA., Baer MR; University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA., Foran JM; Mayo Clinic Comprehensive Cancer Center, Mayo Clinic, Jacksonville, FL, USA., Schiller G; David Geffen School of Medicine at UCLA, Los Angeles, CA, USA., Adès L; Hôpital Saint-Louis (AP-HP) and Université Paris Cité and Centre d'Investigations Cliniques-Inserm CIC-1427, Paris, France., Heiblig M; Centre Hospitalier Lyon Sud, Lyon, France., Berthon C; Centre Hospitalo-Universitaire Lille, Lille, France., Peterlin P; CHU de Nantes-Hôtel-Dieu, Nantes, France., Rodríguez-Arbolí E; Department of Hematology, Hospital Universitario Virgen del Rocío, Seville Biomedicine Institute (IBiS/CSIC), University of Seville, Seville, Spain., Salamero O; Servei d'Hematologia de l'Hospital Vall d'Hebron i Unitat d'Hematología Experimental del Vall d'Hebron Institut d'Oncología, Facultat de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain., Patnaik MM; Mayo Clinic, Rochester, MN, USA., Papayannidis C; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia 'Seràgnoli', Bologna, Italy., Grembecka J; University of Michigan, Ann Arbor, MI, USA., Cierpicki T; University of Michigan, Ann Arbor, MI, USA., Clegg B; University of Michigan, Ann Arbor, MI, USA., Ray J; University of Michigan, Ann Arbor, MI, USA., Linhares BM; University of Michigan, Ann Arbor, MI, USA., Nie K; Kura Oncology, Inc, San Diego, CA, USA., Mitra A; Kura Oncology, Inc, San Diego, CA, USA., Ahsan JM; Kura Oncology, Inc, San Diego, CA, USA., Tabachri M; Kura Oncology, Inc, San Diego, CA, USA., Soifer HS; Kura Oncology, Inc, San Diego, CA, USA., Corum D; Kura Oncology, Inc, San Diego, CA, USA., Leoni M; Kura Oncology, Inc, San Diego, CA, USA., Dale S; Kura Oncology, Inc, San Diego, CA, USA., Fathi AT; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Publikováno v: The Lancet. Oncology [Lancet Oncol] 2024 Oct; Vol. 25 (10), pp. 1310-1324.